Y
Yvonne Wettergren
Researcher at Sahlgrenska University Hospital
Publications - 67
Citations - 1107
Yvonne Wettergren is an academic researcher from Sahlgrenska University Hospital. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 16, co-authored 61 publications receiving 883 citations. Previous affiliations of Yvonne Wettergren include University of Gothenburg.
Papers
More filters
Journal ArticleDOI
Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention
Ashley A. Hibberd,Anna Lyra,Arthur C. Ouwehand,Peter Rolny,Helena Lindegren,Lennart Cedgård,Yvonne Wettergren +6 more
TL;DR: Patients with colon cancer harbour a distinct microbiota signature in the tumour tissue and nearby mucosa, which was altered with probiotic intervention, and results show promise for potential therapeutic benefits in CRC by manipulation of the microbiota.
Journal Article
Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients.
Elisabeth Odin,Yvonne Wettergren,Staffan Nilsson,Roger Willén,Göran Carlsson,C. Paul Spears,Lars Larsson,Bengt Gustavsson +7 more
TL;DR: The results suggest that normal-appearing colonic mucosa adjacent to primary colon cancer can show altered gene expression levels of FPGS that may have bearing on the development of aggressive metastatic behavior of the tumor and on tumor-specific survival.
Journal ArticleDOI
Comparison of bacterial quantities in left and right colon biopsies and faeces
Anna Lyra,Sofia D. Forssten,Peter Rolny,Yvonne Wettergren,Sampo J. Lahtinen,Krista Salli,Lennart Cedgård,Elisabeth Odin,Bengt Gustavsson,Arthur C. Ouwehand +9 more
TL;DR: All detected bacteria, except Enterobacteriaceae, were present at higher levels in the faeces than in the mucosa, but the different locations in the colon presented comparable quantities.
Journal ArticleDOI
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
TL;DR: Assays showing that DPD deficiency impairs breakdown of Ura to dihydrouracil (UH2) seem promising for clinical use, and could prevent severe toxicity otherwise limiting drug administration.
Journal ArticleDOI
A study of the MTHFR gene polymorphism C677T in colorectal cancer.
TL;DR: The MTHFR polymorphism C677T does, in this material, not affect the risk of CRC; however, it can affect the sensitivity to chemotherapy and therisk of side-effects and therefore survival in stage III and possibly stage IV colon cancer.